Skip to main content
WGS
NASDAQ Industrial Applications And Services

GeneDx Confirms CEO Handoff: Cunningham In, Stueland Out by December 15

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$48.01
Mkt Cap
$1.417B
52W Low
$32.21
52W High
$170.87
52W Position info
49% above low
Off High info
72% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

WGS sits 49% above its 52-week low of $32.21 on elevated volume (2.4× avg).

Summary

GeneDx named Everett Cunningham CEO effective on or before December 15, 2026, replacing Katherine Stueland, and disclosed a $750,000 salary, $1.05M sign-on bonus and $20M of equity awards for the incoming chief executive. Full-year 2026 guidance was reaffirmed.


Key Events · Executive and Board Changes · WGS

  • CEO Succession Effective by December 15

    The board appointed Everett Cunningham CEO and a Class II director effective on or before December 15, 2026; Katherine Stueland steps down from both roles that day and stays as Executive Advisor through January 31, 2027.

  • New CEO Pay Package Disclosed

    Cunningham gets a $750,000 base salary, a 100% target bonus (0-150% range), a $1,050,000 sign-on bonus subject to repayment if he leaves within a year, and $20.0M of equity — a $10.0M time-based RSU award plus a $10.0M PRSU award split into four stock-price-hurdle tranches.

  • Outgoing CEO Exit Terms

    Stueland's transition agreement mirrors her existing employment agreement except that, in lieu of salary severance, her RSUs that would have vested in March 2027 accelerate on the Exit Date, subject to a release of claims.

  • Guidance Reaffirmed Despite Transition

    The press release reaffirms full-year 2026 financial guidance as provided on November 9, 2026, alongside Q3 results that showed revenue up 5% to $123.1M and a $12.3M quarterly net loss.


Analysis · WGS · Industrial Applications And Services

GeneDx is swapping CEOs at a delicate moment: Q3 revenue grew 5% to $123.1M but the quarter carried a $12.3M net loss, and Q4 guidance of about $135M came in roughly $7.6M below consensus, sending the stock lower on November 10. The board is handing the company to a career commercial operator — Cunningham ran Quanterix and held senior commercial roles at Illumina, Exact Sciences, Quest and Pfizer — with a mandate to push exome and genome sequencing into first-line standard of care. The price of that hire is real: $750,000 base salary, a $1.05M sign-on bonus, and $20M of equity grants (half time-based, half tied to stock-price hurdles) on top of a ~$4M 2027 refresh target. Stueland exits with accelerated vesting of RSUs that would have vested in March 2027 in place of salary severance, and stays as an advisor through January 31, 2027. Management reaffirmed full-year 2026 guidance, so the transition is not being used to reset expectations — the operating numbers from November 9 still stand.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, WGS was trading at $48.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $32.21 to $170.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WGS - Latest Insights

WGS
Nov 18, 2026, 8:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $47.40
Real-time Price: $49.98 info
Change: +$2.58 (+5%) info
Market Cap: $1.417B info
WGS
Nov 10, 2026, 7:08 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $58.00
Real-time Price: $49.98 info
Change: -$8.02 (-14%) info
Market Cap: $1.417B info
WGS
Nov 09, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $59.00
Real-time Price: $49.98 info
Change: -$9.02 (-15%) info
Market Cap: $1.417B info
WGS
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $65.65
Real-time Price: $49.98 info
Change: -$15.67 (-24%) info
Market Cap: $1.417B info
WGS
Aug 03, 2026, 4:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $77.01
Real-time Price: $49.98 info
Change: -$27.03 (-35%) info
Market Cap: $1.417B info